Our Take
Two URAT1 inhibitors entering the same narrow lane (second-line gout) five days apart signals real demand, not duplication—the market leader sees room for both, but Sobi has Phase III efficacy data and Crystalys does not.
Why it matters
Gout prevalence jumped 22.5% since 1990 and is projected to hit 95.8 million globally by 2050, yet new treatments remain rare. The first company to show clinical benefit (symptom reduction, not just uric acid lowering) in this high-need population may set the standard for second-line therapy.
Do this week
Rheumatologists and payers: wait for Crystalys Phase III tophi and flare data (expected 2027) before committing to either agent; Sobi's full REDUCE-2 results (Q4 2024) and REDUCE-1 readout (H2 2024) will anchor the comparative efficacy bar.
Crystalys starts Phase II as Sobi posts Phase III win
Crystalys Therapeutics dosed its first patient in the AMETHYST Phase II trial of dotinurad on May 26. Five days earlier, Swedish Orphan Biovitrum (Sobi) announced that pozdeutinurad met its primary endpoint in the 811-patient REDUCE-2 trial: 69.2% of patients on the high dose (75 mg) achieved serum uric acid below 6 mg/dL at month 6, versus 8.1% on placebo (p<0.0001) (per Sobi announcement, May 21).
Both molecules are once-daily oral URAT1 inhibitors designed for gout patients who have failed allopurinol, the standard first-line XOI (xanthine oxidase inhibitor) that has dominated treatment since the 1960s. The target population is narrow: roughly 1.5 million Americans (10% of 15 million US gout patients) who cannot tolerate or fail to respond to allopurinol, representing 500,000 to 600,000 patients in the Phase III population, per Crystalys CEO James Mackay.
AMETHYST is a Phase II study enrolling approximately 90 patients with an estimated primary completion date of July 2027. The trial's primary endpoint is the percentage of patients achieving sUA <6.0 mg/dL at week 24. Crystalys is also running two Phase III trials: RUBY (approximately 500 patients, US and EU) and TOPAZ (approximately 250 patients with tophaceous gout, US only), both comparing dotinurad to allopurinol over 64 to 76 weeks.
Sobi has two Phase III trials running in parallel. REDUCE-2 now shows the first efficacy readout; REDUCE-1 (800+ patients, 12 months) is expected to report in H2 2024. Sobi acquired pozdeutinurad through its February 2024 acquisition of Arthrosi Therapeutics for up to $1.5 billion (company-reported). The company projects peak sales of SEK 10 billion ($1.075 billion USD) from the progressive gout population upon launch, expected in 2028.
Sobi has efficacy proof; Crystalys claims a better molecule
Gout prevalence has surged 22.5% between 1990 and 2020, reaching 55.8 million people globally, with 95.8 million projected by 2050 (per 2024 study cited in GEN article). Aging populations and rising metabolic conditions (obesity, hypertension, chronic kidney disease) are driving the increase. Yet recent FDA approvals in gout have been limited to supplemental uses: an expanded label for Krystexxa (pegloticase) in combination with methotrexate (2022) and a new liquid formulation of colchicine (Gloperba, 2023).
Mackay told analysts that Crystalys factored in Sobi's pozdeutinurad when modeling its market entry, assuming 65% market share versus 35% for the competitor assuming equal profiles. He believes dotinurad will outperform: both are URAT1 inhibitors, but dotinurad is more potent, allowing lower doses (2 and 4 mg versus Sobi's 50 and 75 mg). Crystalys claims dotinurad targets URAT1 without affecting OAT1, OAT3, or ABCG2 transporters, which may reduce renal toxicity.
The clinical distinction that matters is symptom control. Sobi's Abad-Franch told analysts she expects "very strong data" on tophi reduction, tophi resolution, and flare reduction in upcoming readouts. Crystalys CEO Mackay said his goal is "to go beyond serum uric acid lowering and actually show that our drug can actually impact the clinical manifestations of the disease, which allopurinol really doesn't do significantly." That positioning—second-line, with clinical benefit over the standard—hinges on Phase III data Crystalys will not deliver until 2027 at earliest.
Phase III efficacy, not Phase II enrollment, is the gating factor
Sobi owns the first-mover advantage in Phase III efficacy reporting. Payers and rheumatologists will likely require proof that either drug reduces flares and tophi burden before covering it as second-line. Sobi's full REDUCE-2 dataset and REDUCE-1 readout (both expected by end of 2024) will establish the efficacy floor. Crystalys will need to match or exceed those benchmarks in RUBY and TOPAZ to justify market share in a space both companies agree is large enough for competition.
The broader pipeline underscores the unmet need: over 25 novel gout drugs are in development across 20+ companies, ranging from NLRP3 inhibitors (dapansutrile, Olatec) to other URAT1 selective inhibitors (epaminurad, JW Pharmaceutical). However, most remain in Phase II or earlier. Sobi's acquisition of Arthrosi and its dual-track Phase III strategy position it to reach market first with published efficacy data—a meaningful advantage in a therapeutic area starved for new options.